Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Hong Kong Stock Movement | WuXi AppTec (02268) rises over 7% after earnings, revenue and net profit both grow in 2025 CRDMO business continues to show strong momentum
WuXi AppTec (02268) shares rose over 7% after earnings release. As of press time, it was up 6.5%, trading at HKD 54.15, with a turnover of HKD 33.76 million.
On the news front, on March 23, WuXi AppTec announced its 2025 financial results, with revenue of approximately RMB 5.944 billion, up 46.7% year-on-year; gross profit of about RMB 2.139 billion, up 72.5%; adjusted net profit attributable to owners of the company of approximately RMB 1.559 billion, up 69.9%; net profit increased 38.4% year-on-year to RMB 1.48 billion. The total value of unfulfilled orders also increased by 50.3% from USD 991 million as of December 31, 2024, to USD 1.489 billion as of December 31, 2025.
The announcement states that the group’s CRDMO business continued to show strong momentum in 2024 and 2025, with ongoing active expansion and increased global customer demand for its services. As of December 31, 2025, leveraging its comprehensive CRDMO capabilities and facilities equipped with a one-stop function from drug discovery to commercialization, the group has empowered a total of 643 global clients through integrated services. The group has successfully secured 18 PPQ (Process Validation) projects and 1 commercialization project.